In response to your post, my research show that the CEO Frank Reynolds was already making regular public comments indicating that he expected the human clinical trials “to begin next year” as early as 2008 (i.e., not 2009 as I erroneously stated in my post of 3 days ago). Thus, by now he has projected approval to be literally “a few months away” for over 3 years. I call that overpromising and underdelivering.
Market Data 
Markets 
AI
